News

RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships

  • New role highlights RenovoRx's commitment to explore and execute on clinical and commercial business development opportunities with its therapeutic technology New role highlights RenovoRx's commitment to explore and execute on clinical and commercial business development opportunities with its therapeutic technology
    06/10/2024

RenovoRx CEO Issues Update Letter to Shareholders

  • LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today provided a letter to shareholders from Chief Executive Officer, Shaun Bagai. Dear Fellow RenovoRx Shareholders, The first quarter of 2024 marked a significant period in our company's evolution, and we have set the stage for significant milestones in the foreseeable.
    05/30/2024
Profitability
Dividends
Income Statement
Balance Sheet
Cash Flow Statement
Symbol Frequently Asked Questions

RenovoRx, Inc. (RNXT) can hold. Click on Rating Page for detail.

The price of RenovoRx, Inc. (RNXT) is 1.33 and it was updated on 2024-06-17 09:00:56.

Currently RenovoRx, Inc. (RNXT) is in undervalued.

News
    
News

Publication of Results of Pre-Clinical Studies Support Efficacy and Drug Delivery Mechanism Potential of RenovoRx's TAMP™ Therapy Platform to Improve Targeted Cancer Drug Treatment Delivery

  • LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced a publication of pre-clinical studies supporting the efficacy and drug delivery mechanism of RenovoRx's Trans-Arterial Micro-Perfusion (“TAMP”) therapy platform. The data was published online in the peer-reviewed Journal of Vascular Interventional Radiolog.
    Tue, May. 21, 2024

RenovoRx to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase on May 21, 2024

  • LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced that Shaun Bagai, Chief Executive Officer, will participate in a fireside chat at Alliance Global Partners (A.G.P.) Virtual Healthcare Company Showcase hosted by Scott Henry, Managing Director and Healthcare Analyst at A.G.P. The event will be held on Tues.
    Tue, May. 14, 2024

RenovoRx CEO Shaun R. Bagai to Present at the Aegis Capital Virtual Conference on May 9, 2024

  • LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced that Shaun R. Bagai, Chief Executive Officer, will present at the Aegis Capital Virtual Conference being held on May 7-9, 2024. Mr. Bagai will discuss recent corporate milestones, including the completion of private placements in January and April 2024 in.
    Thu, May. 02, 2024

RenovoRx Regains Compliance with Nasdaq Stockholders' Equity Requirement

  • LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced that, in light of its recent successful fundraising activity, it has received written confirmation from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with the $2.5 million minimum stockholders' equity requirement in Nasdaq.
    Thu, Apr. 18, 2024

RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting

  • LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today highlights a presentation of a clinical data abstract at the recent 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting, held March 23-27, 2024 in Salt Lake City, Utah. Clinical data was presented by David Sperling, MD, Associate Professor of Ra.
    Tue, Apr. 16, 2024
SEC Filings
SEC Filings

RenovoRx, Inc. (RNXT) - EFFECT

  • SEC Filings
  • 05/13/2024

RenovoRx, Inc. (RNXT) - EFFECT

  • SEC Filings
  • 05/13/2024

RenovoRx, Inc. (RNXT) - 424B3

  • SEC Filings
  • 05/10/2024

RenovoRx, Inc. (RNXT) - DEF 14A

  • SEC Filings
  • 04/30/2024

RenovoRx, Inc. (RNXT) - S-3

  • SEC Filings
  • 04/26/2024

RenovoRx, Inc. (RNXT) - D

  • SEC Filings
  • 04/22/2024

RenovoRx, Inc. (RNXT) - S-3

  • SEC Filings
  • 04/19/2024

RenovoRx, Inc. (RNXT) - S-8

  • SEC Filings
  • 04/12/2024

RenovoRx, Inc. (RNXT) - 4

  • SEC Filings
  • 03/08/2024

RenovoRx, Inc. (RNXT) - 3

  • SEC Filings
  • 03/08/2024

RenovoRx, Inc. (RNXT) - 4

  • SEC Filings
  • 02/12/2024

RenovoRx, Inc. (RNXT) - 3

  • SEC Filings
  • 02/12/2024

RenovoRx, Inc. (RNXT) - D

  • SEC Filings
  • 02/09/2024

RenovoRx, Inc. (RNXT) - 4

  • SEC Filings
  • 01/30/2024

RenovoRx, Inc. (RNXT) - 4

  • SEC Filings
  • 01/23/2024

RenovoRx, Inc. (RNXT) - DEF 14A

  • SEC Filings
  • 11/27/2023

RenovoRx, Inc. (RNXT) - PRE 14A

  • SEC Filings
  • 11/17/2023

RenovoRx, Inc. (RNXT) - 4

  • SEC Filings
  • 10/04/2023

RenovoRx, Inc. (RNXT) - 4

  • SEC Filings
  • 10/02/2023

RenovoRx, Inc. (RNXT) - EFFECT

  • SEC Filings
  • 05/22/2023

RenovoRx, Inc. (RNXT) - 424B3

  • SEC Filings
  • 05/19/2023

RenovoRx, Inc. (RNXT) - S-3

  • SEC Filings
  • 05/12/2023

RenovoRx, Inc. (RNXT) - DEF 14A

  • SEC Filings
  • 05/01/2023

RenovoRx, Inc. (RNXT) - 4

  • SEC Filings
  • 04/27/2023

RenovoRx, Inc. (RNXT) - 3

  • SEC Filings
  • 04/27/2023

RenovoRx, Inc. (RNXT) - S-8 POS

  • SEC Filings
  • 04/03/2023

RenovoRx, Inc. (RNXT) - 424B5

  • SEC Filings
  • 04/03/2023

RenovoRx, Inc. (RNXT) - S-8

  • SEC Filings
  • 03/31/2023

RenovoRx, Inc. (RNXT) - 4

  • SEC Filings
  • 03/29/2023

RenovoRx, Inc. (RNXT) - SC 13G/A

  • SEC Filings
  • 02/14/2023

RenovoRx, Inc. (RNXT) - EFFECT

  • SEC Filings
  • 11/22/2022

RenovoRx, Inc. (RNXT) - EFFECT

  • SEC Filings
  • 11/22/2022

RenovoRx, Inc. (RNXT) - 424B3

  • SEC Filings
  • 11/22/2022

RenovoRx, Inc. (RNXT) - S-3

  • SEC Filings
  • 11/10/2022

RenovoRx, Inc. (RNXT) - S-1

  • SEC Filings
  • 11/10/2022

RenovoRx, Inc. (RNXT) - 4

  • SEC Filings
  • 11/04/2022

RenovoRx, Inc. (RNXT) - 4

  • SEC Filings
  • 10/04/2022

RenovoRx, Inc. (RNXT) - 4

  • SEC Filings
  • 09/21/2022

RenovoRx, Inc. (RNXT) - 3

  • SEC Filings
  • 07/20/2022

RenovoRx, Inc. (RNXT) - 4

  • SEC Filings
  • 06/17/2022

RenovoRx, Inc. (RNXT) - 3/A

  • SEC Filings
  • 06/17/2022

RenovoRx, Inc. (RNXT) - 4

  • SEC Filings
  • 06/09/2022

RenovoRx, Inc. (RNXT) - 4

  • SEC Filings
  • 05/23/2022

RenovoRx, Inc. (RNXT) - DEF 14A

  • SEC Filings
  • 04/29/2022

RenovoRx, Inc. (RNXT) - SC 13G

  • SEC Filings
  • 04/14/2022

RenovoRx, Inc. (RNXT) - 3

  • SEC Filings
  • 04/14/2022

RenovoRx, Inc. (RNXT) - S-8

  • SEC Filings
  • 03/30/2022

RenovoRx, Inc. (RNXT) - 4

  • SEC Filings
  • 03/14/2022

RenovoRx, Inc. (RNXT) - SC 13G

  • SEC Filings
  • 02/14/2022

RenovoRx, Inc. (RNXT) - SC 13G

  • SEC Filings
  • 02/10/2022

RenovoRx, Inc. (RNXT) - S-8

  • SEC Filings
  • 10/29/2021

RenovoRx, Inc. (RNXT) - 4

  • SEC Filings
  • 10/05/2021

RenovoRx, Inc. (RNXT) - 4

  • SEC Filings
  • 10/04/2021

RenovoRx, Inc. (RNXT) - 3

  • SEC Filings
  • 08/30/2021

RenovoRx, Inc. (RNXT) - 424B4

  • SEC Filings
  • 08/27/2021

RenovoRx, Inc. (RNXT) - EFFECT

  • SEC Filings
  • 08/26/2021

RenovoRx, Inc. (RNXT) - EFFECT

  • SEC Filings
  • 08/25/2021

RenovoRx, Inc. (RNXT) - S-1/A

  • SEC Filings
  • 08/25/2021

RenovoRx, Inc. (RNXT) - CORRESP

  • SEC Filings
  • 08/25/2021

RenovoRx, Inc. (RNXT) - 3

  • SEC Filings
  • 08/25/2021

RenovoRx, Inc. (RNXT) - CORRESP

  • SEC Filings
  • 08/24/2021

RenovoRx, Inc. (RNXT) - CERT

  • SEC Filings
  • 08/24/2021

RenovoRx, Inc. (RNXT) - CORRESP

  • SEC Filings
  • 08/20/2021

RenovoRx, Inc. (RNXT) - S-1/A

  • SEC Filings
  • 08/19/2021

RenovoRx, Inc. (RNXT) - S-1/A

  • SEC Filings
  • 08/12/2021

RenovoRx, Inc. (RNXT) - CORRESP

  • SEC Filings
  • 08/12/2021

RenovoRx, Inc. (RNXT) - 8-A12B

  • SEC Filings
  • 08/11/2021

RenovoRx, Inc. (RNXT) - CORRESP

  • SEC Filings
  • 08/10/2021

RenovoRx, Inc. (RNXT) - S-1/A

  • SEC Filings
  • 08/05/2021

RenovoRx, Inc. (RNXT) - CORRESP

  • SEC Filings
  • 08/05/2021

RenovoRx, Inc. (RNXT) - UPLOAD

  • SEC Filings
  • 07/29/2021

RenovoRx, Inc. (RNXT) - S-1

  • SEC Filings
  • 07/21/2021

RenovoRx, Inc. (RNXT) - DRSLTR

  • SEC Filings
  • 06/15/2021

RenovoRx, Inc. (RNXT) - DRS/A

  • SEC Filings
  • 06/15/2021

RenovoRx, Inc. (RNXT) - UPLOAD

  • SEC Filings
  • 05/28/2021

RenovoRx, Inc. (RNXT) - DRSLTR

  • SEC Filings
  • 05/12/2021

RenovoRx, Inc. (RNXT) - DRS/A

  • SEC Filings
  • 05/12/2021

RenovoRx, Inc. (RNXT) - UPLOAD

  • SEC Filings
  • 05/03/2021

RenovoRx, Inc. (RNXT) - DRS

  • SEC Filings
  • 04/02/2021

RenovoRx, Inc. (RNXT) - D

  • SEC Filings
  • 06/19/2018

RenovoRx, Inc. (RNXT) - D

  • SEC Filings
  • 01/05/2016

RenovoRx, Inc. (RNXT) - D

  • SEC Filings
  • 12/23/2013

RenovoRx, Inc. (RNXT) - D

  • SEC Filings
  • 04/10/2013
Press Releases
StockPrice Release
More Headlines
News

RenovoRx Closes $11.1 Million Private Placement, Providing Cash Runway into 2026

  • LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced the closing of its previously announced private placement of approximately $11.1 million in gross proceeds. Shaun Bagai, Chief Executive Officer of RenovoRx, stated, “We believe our recent financing achievements mark a critical milestone for RenovoRx. Our.
  • 04/15/2024

RNXT Stock Earnings: RenovoRx Meets EPS for Q4 2023

  • RenovoRx (NASDAQ: RNXT ) just reported results for the fourth quarter of 2023. RenovoRx reported earnings per share of -30 cents.
  • 04/08/2024

RenovoRx Announces $11.1 Million at Market Private Placement

  • LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced the execution of definitive subscription agreements with accredited investors for a private placement which is expected to result in gross proceeds of approximately $11.1 million to RenovoRx, before deducting offering expenses. The proceeds from this finan.
  • 04/08/2024

RenovoRx to Present at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 15, 2024

  • LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced that Shaun Bagai, RenovoRx's Chief Executive Officer, will present at the Canaccord Genuity 2024 Horizons in Oncology Virtual Conference to be held on April 15, 2024. Mr. Bagai will meet with investors and participate in a panel discussion hosted by Bill M.
  • 04/05/2024

RenovoRx Highlights Key Leadership Promotions

  • LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today highlighted the recent key leadership promotions of Leesa Gentry to Chief Clinical Officer and Ronald B. Kocak, CPA to Principal Accounting Officer. Shaun Bagai, Chief Executive Officer of RenovoRx, commented, “We are delighted to promote Leesa and Ron to their new.
  • 03/08/2024

RenovoRx CEO Issues Letter to Shareholders

  • LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today provided a letter to shareholders from Chief Executive Officer, Shaun Bagai. Dear Fellow RenovoRx Shareholders, 2023 was a pivotal year for RenovoRx, and we believe our accomplishments bode well for the achievement of our anticipated 2024 milestones. Our team worked.
  • 02/06/2024

RenovoRx Closes $6.1 Million Private Placement

  • LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced that it has closed a private placement (the “private placement” or the “financing”) resulting in gross proceeds of approximately $6.1 million, before deducting offering expenses. The closing of this private placement extends RenovoRx's cash runway as Renov.
  • 01/29/2024

RenovoRx Engages Oklahoma University (OU) Health as First Clinical Site in Preparation for the Pivotal Phase III CouGar Clinical Trial in Bile Duct Cancer

  • LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced the expansion of their clinical development pipeline in preparation for the commencement of a second Phase III trial. The CouGar Trial will evaluate RenovoGem in bile duct cancer, specifically unresectable locally advanced extrahepatic cholangiocarcinoma (.
  • 12/21/2023

RenovoRx Announces Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting

  • LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced the acceptance of a clinical data abstract for the 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting, held March 23-28 in Salt Lake City, Utah. The abstract will highlight the Company's lead product candidate, RenovoGem, and proprietary Trans-Arterial Micro-Perfu.
  • 12/19/2023

RenovoRx Files New International Patent for Novel Targeted Combination Drug-Delivery Oncology Therapy Platform

  • LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced today that the Company has filed an international patent application under the Patent Cooperation Treaty (PCT) for its novel Trans-Arterial Micro-Perfusion (TAMP) therapy platform. The Company already holds a strong intellectual property portfolio with 9 issued patents and 9 pending patents.
  • 12/13/2023

RenovoRx Expands Scientific Advisory Board with Appointment of Michel Ducreux, M.D., Ph.D.

  • LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced the appointment of Michel Ducreux, M.D., Ph.D. to the Company's Scientific Advisory Board (SAB). Dr. Ducreux is the Head of the Gastrointestinal Oncology Unit and Gastrointestinal Oncology Tumor Board at Gustave Roussy, Professor of Oncology at Paris-Saclay University in France, and Vice-Chair of ES.
  • 11/16/2023

RenovoRx Reports Third Quarter 2023 Financial Results and Operational Highlights

  • LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced financial results for the third quarter ended September 30, 2023. “We remain focused on our core mission to improve the lives of patients diagnosed with difficult-to-treat cancers by delivering novel targeted combination therapies that have the potential to alter the current paradigm of oncology car.
  • 11/14/2023

RenovoRx to Present at the ROTH MKM Healthcare Opportunities Conference on October 12, 2023

  • LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced that CEO, Shaun Bagai, will present at the ROTH MKM Healthcare Opportunities Conference in New York on October 12, 2023. Register here. Moderated by Scott Henry, Managing Director, Senior Research Analyst & Head of Pharmaceuticals Research at ROTH Capital Partners, LLC, will conduct a fireside c.
  • 10/02/2023

RenovoRx Reports Second Quarter 2023 Financial Results and Operational Highlights

  • LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced financial results for the second quarter ended June 30, 2023. “We made strong progress this quarter and have continued momentum in our commitment to transform the lives of patients by delivering innovative solutions to change the current paradigm of cancer care,” said Shaun Bagai, CEO of RenovoRx. “.
  • 08/17/2023

RenovoRx to Present at the 43rd Annual Canaccord Genuity Growth Conference

  • LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced that its CEO Shaun Bagai will provide a corporate overview and update at the 43rd Annual Canaccord Genuity Growth Conference on Thursday, August 10, 2023 at 10:30 AM ET in Boston, MA. Register here to access the live webcast. Mr. Bagai will discuss recent Company milestones, including the research c.
  • 07/31/2023

RenovoRx to Participate in the Aegis Capital Virtual Conference on May 3, 2023

  • LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of solid tumors, announced that Shaun Bagai, CEO of RenovoRx, will present at the Aegis Capital Virtual Conference on May 3rd at 3:30 p.m. ET. The online presentation can be accessed here. The conference will be held May 2-4, 2023. Mr. Bagai will provide a corporate update including recently announced positive interim data for the Compan.
  • 04/28/2023

RenovoRx to Present at the 35th Annual Roth Conference on March 13, 2023

  • LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of solid tumors, today announces that Shaun Bagai, Chief Executive Officer, will be presenting at the 35th Annual Roth Conference, to be held March 12-14, 2023, in Dana Point, California. To register for the event, visit the conference website. During the presentation, Mr.
  • 03/01/2023

RenovoRx to Present at the Sequire Biotechnology Virtual Conference on February 2, 2023

  • LOS ALTOS, Calif.--( BUSINESS WIRE )--RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of solid tumors, today announced that Shaun Bagai, Chief Executive Officer, is scheduled to present virtually at the Sequire Biotechnology Conference on Thursday, February 2, 2023 at 4 p.m. (ET). To register for the event, visit the Sequire Biotechnology Conference website.
  • 01/25/2023

RenovoRx to Present Preclinical Research Data Demonstrating its Innovative Therapy Platform's Potential Utility for the Treatment of Bile Duct Cancer

  • LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announces that it will present preclinical research supporting its planned second clinical indication, bile duct cancer, also known as cholangiocarcinoma, at the Global Embolization Oncology Symposium Technologies (GEST) 2022, today in New York City. The study demonstrates the potential utility of RenovoRx's proprietary Tran
  • 05/19/2022

RenovoRx to Participate in March 2022 Investor Conferences

  • LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced its leadership's participation in two upcoming Investor Conferences this month. ROTH Capital Partners 34th Annual Conference Format and Dates: In person, March 13-15, 2022 Location: The Ritz Carlton Laguna Niguel Hotel, Dana Point, CA Presenters and Presentation Date/Time: Shaun Bagai, CEO, to present on Monday, Ma
  • 03/11/2022

5 Short Squeeze Candidates To Watch: Pioneer Power, NuZee Remain At The Top, Grab Rejoins The Leaderboard

  • Potential short squeeze plays have gained steam in 2021 with new retail traders looking for the next huge move. GameStop Corp (NYSE:GME) and AMC Entertainment Holdings (NYSE:AMC) are two high-profile examples of short squeezes earlier this year.
  • 12/06/2021

Short Squeeze Stocks: PPSI, NUZE and 3 Others Experts Think Are Ready to Pop

  • PPSI, NUZE, and three other stocks are ranked highly in Fintel's Short Squeeze Screener. All three names have a score higher than 96.
  • 11/29/2021

5 Short Squeeze Candidates To Watch: Pioneer Power Tops List Along With Newegg, Nuzee And More

  • Potential short squeeze plays have gained steam in 2021 with new retail traders looking for the next huge move. GameStop Corp (NYSE: GME) and AMC Entertainment Holdings (NYSE: AMC) are two high-profile examples of short squeezes earlier this year.
  • 11/29/2021

RenovoRx (RNXT) Stock: Why The Price Surged Over 130% Today

  • The stock price of RenovoRx Inc (NASDAQ: RNXT) increased by over 130% during intraday trading today. This is why it happened.
  • 11/10/2021

Dear FSR Stock Fans, Mark Your Calendars for an EV Catalyst on Nov. 17

  • Fisker (FSR) investors are going to want to keep an eye on FSR stock when Nov. 17 rolls around next Wednesday for a big reveal. The post Dear FSR Stock Fans, Mark Your Calendars for an EV Catalyst on Nov. 17 appeared first on InvestorPlace.
  • 11/10/2021

RNXT Stock Alert: 5 Things to Know as RenovoRx Soars 100%+ Today

  • RenovoRx (RNXT) stock is rocketing higher today thanks to a presentation of data at a medical conference yesterday evening. The post RNXT Stock Alert: 5 Things to Know as RenovoRx Soars 100%+ Today appeared first on InvestorPlace.
  • 11/10/2021

RNXT Stock: The FDA News That Has Biotech Company RenovoRx Rocketing Higher Today

  • RenovoRx (RNXT) stock is running higher on Tuesday following news that the U.S. Food and Drug Administration granted it new 501(k) clearance. The post RNXT Stock: The FDA News That Has Biotech Company RenovoRx Rocketing Higher Today appeared first on InvestorPlace.
  • 09/07/2021

RNXT Stock: Over 50% Increase Pre-Market Explanation

  • The stock price of RenovoRx Inc (NASDAQ: RNXT) increased by over 50% pre-market. This is why it happened.
  • 09/07/2021

See Why RenovoRx Stock Is Shooting Higher On Tuesday

  • The FDA has granted a new 510(k) clearance to RenovoRx Inc's (NASDAQ:RNXT) RenovoCath Delivery System.  The RenovoCath Delivery System is the device component of the Company's initial product, RenovoGem.
  • 09/07/2021

RenovoRx Receives New 510(k) Clearance for its RenovoCath® Delivery System Designed for Targeted Treatment of Solid Tumors

  • LOS ALTOS, Calif., Sept. 7, 2021 /PRNewswire/ --  RenovoRx , Inc. (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced it has received a new 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its proprietary RenovoCath Delivery System.
  • 09/07/2021

RenovoRx Proposes Terms For $22 Million IPO

  • RenovoRx has filed to raise $22.2 million in an IPO. The firm is in Phase 3 clinical trials for its novel drug delivery system for cancer treatments.
  • 08/13/2021
Unlock
RNXT Ratings Summary
RNXT Quant Ranking